|
1. Robson, N.C., Phillips, D.J., Mcalpine, T., Shin, A., Svobodova, S., Toy, T., Pillay, V., Kirkpatrick, N., Zanker, D., Wilson, K., Helling, I., Wei, H., Chen, W., Cebon, J., and Maraskovsky, E., Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood, 111(5): p. 2733-43 2008.
2. John, T., Caballero, O.L., Svobodova, S.J., Kong, A., Chua, R., Browning, J., Fortunato, S., Deb, S., Hsu, M., Gedye, C.A., Davis, I.D., Altorki, N., Simpson, A.J., Chen, Y.T., Monk, M., and Cebon, J.S., ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clin Cancer Res, 14(11): p. 3291-8 2008.
3. John, T., Black, M.A., Toro, T.T., Leader, D., Gedye, C.A., Davis, I.D., Guilford, P.J., and Cebon, J.S., Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res, 14(16): p. 5173-80 2008.
4. Davis, I.D., Skrumsager, B.K., Cebon, J., Nicholaou, T., Barlow, J.W., Moller, N.P., Skak, K., Lundsgaard, D., Frederiksen, K.S., Thygesen, P., and Mcarthur, G.A., An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res, 13(12): p. 3630-6 2007.
5. Cebon, J., Gedye, C., John, T., and Davis, I.D., Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol, 5(12): p. 994-1006 2007.
6. Nicholaou, T., Ebert, L., Davis, I.D., Robson, N., Klein, O., Maraskovsky, E., Chen, W., and Cebon, J., Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol, 84(3): p. 303-17 2006.
 Click Here For More
|
